Immunovia AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was SEK 0.488 million compared to SEK 0.358 million a year ago. Revenue was SEK 0.579 million compared to SEK 0.381 million a year ago. Net loss was SEK 38.56 million compared to SEK 22.93 million a year ago. Basic loss per share from continuing operations was SEK 0.91 compared to SEK 1.01 a year ago. Diluted loss per share from continuing operations was SEK 0.91 compared to SEK 1.01 a year ago.
For the nine months, sales was SEK 1.42 million compared to SEK 0.643 million a year ago. Revenue was SEK 1.59 million compared to SEK 0.691 million a year ago. Net loss was SEK 260.42 million compared to SEK 100.77 million a year ago. Basic loss per share from continuing operations was SEK 7.99 compared to SEK 4.45 a year ago. Diluted loss per share from continuing operations was SEK 7.99 compared to SEK 4.45 a year ago.